公开(公告)号：US20220281899A1

公开(公告)日：2022-09-08

申请号：US17742390

申请日：2022-05-11

Applicant: FUJIFILM Corporation

Inventor： Hiyoku NAKATA ,  Masato SAKAKIBARA ,  Akihiro ASAKURA ,  Keiko MAKITA

IPC: C07F5/02 ,  A61K49/00

Abstract: Provided are the following compound and a fluorescently labeled biological substance having this fluorescent compound. X represents CR7 or N.
R1 to R7, Q1, and Q2 represent a hydrogen atom, a halogen atom, a cyano group, or a group represented by Formula (A), and adjacent substituents may form a ring structure.
However, at least one of R3, R4, R7, Q1, or Q2 contains, as a hydrophilic group, at least one of a carboxy group or a salt thereof, a sulfo group or a salt thereof, a phosphono group or a salt thereof, an onio group, or a polyamino acid residue, where at least one of Q1 or Q2 represents an alkyl group.

公开(公告)号：US20180296485A1

公开(公告)日：2018-10-18

申请号：US16013355

申请日：2018-06-20

Applicant: FUJIFILM Corporation

Inventor： Naoki YAMADA ,  Keiko MAKITA ,  Eriko WATANABE ,  Takuya INOUE

IPC: A61K9/127 ,  A61K47/24 ,  A61K47/10 ,  A61K31/704

Abstract: An object of the present invention is to provide a liposome and a liposome composition in which release of a drug in blood is suppressed during accumulation of the liposome and the liposome composition in a target site such as a tumor and the drug is rapidly removed after the liposome and the liposome composition are sufficiently accumulated. According to the present invention, there is provided a liposome containing at least a phospholipid to which a hydrophilic polymer is bonded, a phospholipid having a negative charge within a range of a pH of 6 to 8, and a phospholipid which is electrically neutral within a range of a pH of 6 to 8, in which an average carbon chain length of the phospholipid to which the above-described hydrophilic polymer is bonded is shorter than an average carbon chain length of the above-described phospholipid which is electrically neutral within a range of a pH of 6 to 8.

公开(公告)号：US20210088526A1

公开(公告)日：2021-03-25

申请号：US17105638

申请日：2020-11-27

Applicant: FUJIFILM Corporation

Inventor： Hiyoku NAKATA ,  Kousuke WATANABE ,  Akihiro ASAKURA ,  Keiko MAKITA ,  Yoshinori KANAZAWA ,  Kazuhei KANEKO

IPC: G01N33/58 ,  C09K11/06 ,  C09B23/06 ,  G01N21/64

Abstract: Provided are any one of the following fluorescent compounds and a fluorescent labeled biological substance having this fluorescent compound. X represents CR5 or N, and R1 to R7, Q1, Q2, L1, and L2 each represent a specific group.
a ring β1 and a ring β2 are a 5- to 8-membered ring,
At least one of R1 to R7, L1, L2, Q1, or Q2 has a specific hydrophilic group.
However, in a case where the ring β1 and the ring β2 are a 6-membered ring, and L1 and L2 are an arylene group, R5 is not an aryl group substituted with a linear alkyl group having 18 or more carbon atoms. In addition to the regulation of the ring β1, the ring β2, L1, and L2, in a case where R5 has a substituent having a dipyrromethene boron complex structure, the dipyrromethene boron complex structure has a structure in which a dipyrromethene skeleton is coordinately bonded to a boron atom in the tridentate or tetradentate coordination.

公开(公告)号：US20190314360A1

公开(公告)日：2019-10-17

申请号：US16453393

申请日：2019-06-26

Applicant: FUJIFILM Corporation ,  FUJIFILM Toyama Chemical Co., Ltd. ,  NATIONAL INSTITUTE OF ADVANCED INDUSTRIAL SCIENCE AND TECHNOLOGY

Inventor： Keiko MAKITA ,  Kazunori SAEKI ,  Tadashi TANAKA ,  Masataka FUJINO ,  Tohru NATSUME ,  Kentaro FURUYA

IPC: A61K31/4704 ,  A61K31/5377 ,  A61K31/4709 ,  A61K31/4725 ,  A61K31/498 ,  A61K31/497 ,  A61P35/02 ,  A61P35/00

Abstract: It is an object of the present invention to provide an antitumor agent, which is further excellent as a treatment agent used in the prevention and/or therapy of tumor associated with a bromodomain, and also to provide a bromodomain inhibitor, which is useful as a treatment agent for diseases or states associated with a bromodomain.An antitumor agent and a bromodomain inhibitor, comprising a compound represented by the following formula, have an excellent bromodomain inhibitory activity and are useful as treatment agents in the prevention and/or therapy of tumor associated with a bromodomain, and the like: wherein R1 represents a C1-6 alkyl group, etc.; R2 represents a hydrogen atom, etc.; R3 represents a halogen atom, etc.; Z1, Z2 and Z3 each represent CH, etc.; X1 represents CONH, etc.; Ring A represents a phenyl group, etc.; R4 represents a halogen atom, etc.; and m represents an integer from 0 to 5.